



Equivalent of Form PTO/SB/08A (09-06)
Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	10/535,458 (U.S. Nat'l Phase of Int'l Appl. No. PCT/US03/37206)
Int'l Filing Date	November 20, 2003
First Named Inventor	MCLACHLAN, Karen
Art Unit	1646
Examiner Name	<i>To Be Assigned</i>
Attorney Docket Number	2159.0640005/EKS/PAC/DLL

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

625593 1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/535,458 (U.S. Nat'l Phase of Int'l Appl. No. PCT/US03/37206)
				Int'l Filing Date	November 20, 2003
				First Named Inventor	MCLACHLAN, Karen
				Art Unit	1646
				Examiner Name	To Be Assigned
Sheet	1	of	4	Attorney Docket Number	2159.0640005/EKS/PAC/DLL

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	Dia, B., <i>et al.</i> , "Gastrin Gene Expression in Human Colon Cancer Cells: Autocrine Role of Gastrin," <i>Gastroenterology</i> 102:A352, W.B. Saunders (1992)	
	NPL2	Eggstein, S., <i>et al.</i> , "Influence of gastrin, gastrin receptor blockers, epidermal growth factor, and difluoromethylornithine on the growth and the activity of ornithine decarboxylase of colonic carcinoma cells," <i>J. Cancer Res. Clin. Oncol.</i> 117:37-42, Springer Verlag (1991)	
	NPL3	Fearon, E.R. and Vogelstein, B., "A genetic model for colorectal tumorigenesis," <i>Cell</i> 61:759-767, Cell Press (1990)	
	NPL4	Finley, G.G., <i>et al.</i> , "Expression of the Gastrin Gene in the Normal Human Colon and Colorectal Adenocarcinoma," <i>Cancer Res.</i> 53:2919-2926, American Association for Cancer Research (1993)	
	NPL5	Guo, Y.-S., <i>et al.</i> , "Growth-Promoting Effects of Gastrin on Mouse Colon Cancer Cells In Vitro: Absence of Autocrine Effects," <i>In Vitro Cell. Dev. Biol.</i> 26:871-877, Tissue Culture Association (1990)	
	NPL6	Hoosein, N.M., <i>et al.</i> , "Antiproliferative Effects of Gastrin Receptor Antagonists and Antibodies to Gastrin on Human Colon Carcinoma Cell Lines," <i>Cancer Res.</i> 48:7179-7183, American Association for Cancer Research (1988)	
	NPL7	Hoosein, N.M., <i>et al.</i> , "Evidence for Autocrine Growth Stimulation of Cultured Colon Tumor Cells by a Gastrin/Cholecystokinin-like Peptide," <i>Exp. Cell Res.</i> 186:15-21, Academic Press (1990)	
	NPL8	Ishizuka, J., <i>et al.</i> , "Effects of Gastrin on 3',5'-Cyclic Adenosine Monophosphate, Intracellular Calcium, and Phosphatidylinositol Hydrolysis in Human Colon Cancer Cells," <i>Cancer Res.</i> 54:2129-2135, American Association for Cancer Research (1994)	
	NPL9	Karlin, D.A., <i>et al.</i> , "Hypergastrinaemia and Colorectal Carcinogenesis in the Rat," <i>Cancer Lett.</i> 29:73-78, Elsevier Science Ireland (1985)	
	NPL10	Kochman, M.L., <i>et al.</i> , "Post-Translational Processing of Gastrin in Neoplastic Human Colonic Tissues," <i>Biochem. Biophys. Res. Commun.</i> 189:1165-1169, Academic Press (1992)	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/535,458 (U.S. Nat'l Phase of Int'l Appl. No. PCT/US03/37206)
				Int'l Filing Date	November 20, 2003
				First Named Inventor	MCLACHLAN, Karen
				Art Unit	1646
				Examiner Name	To Be Assigned
Sheet	2	of	4	Attorney Docket Number	2159.0640005/EKS/PAC/DLL

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL11	Kusyk, C.J., <i>et al.</i> , "Stimulation of growth of a colon cancer cell line by gastrin," <i>Am. J. Physiol.</i> 251:G597-G601, American Physiological Society (1986)	
	NPL12	Lamote, J. and Willems, G., "Stimulating effect of a pentagastrin on cancer cell proliferation kinetics in chemically induced colon cancer in rats," <i>Regul. Pept.</i> 20:1-9, Elsevier/north Holland (1988)	
	NPL13	Montag, <i>et al.</i> , "Tumors in hepatobiliary tract and pancreatic islet tissues of transgenic mice harboring gastrin simian virus 40 tumor large antigen fusion gene," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:6696-9700, National Academy of Sciences (1993)	
	NPL14	Rehfeld, J.F. and Van Solinge, W.W., "The Tumor Biology of Gastrin and Cholecystokinin," <i>Adv. Cancer Res.</i> 63:295-347, Academic Press (1994)	
	NPL15	Singh, P., <i>et al.</i> , "Gastrin Receptors in a Mouse Colon Cancer Cell Line Responsive to Trophic Effects of Gastrin," <i>Surg. Forum</i> 35:205-206, American College of Surgeons (1984)	
	NPL16	Singh, P., <i>et al.</i> , "Gastrin receptors in normal and malignant gastrointestinal mucosa: age-associated changes," <i>Am. J. Physiol.</i> 249:G761-G769, American Physiological Society (1985)	
	NPL17	Singh, P., <i>et al.</i> , "Role of Gastrin and Gastrin Receptors on the Growth of a Transplantable Mouse Colon Carcinoma (MC-26) in BALB/c Mice," <i>Cancer Res.</i> 46:1612-1616, American Association for Cancer Research (1986)	
	NPL18	Singh, P., <i>et al.</i> , "Inhibition of Pentagastrin-stimulated Up-Regulation of Gastrin Receptors and Growth of Mouse Colon Tumor <i>in Vivo</i> by Proglumide, a Gastrin Receptor Antagonist," <i>Cancer Res.</i> 47:5000-5004, American Association for Cancer Research (1987)	
	NPL19	Singh, P., <i>et al.</i> , "Gut hormones in colon cancer: past and prospective studies," <i>Cancer J</i> 3:28-33, Lippincott Williams & Wilkins (1990)	
	NPL20	Singh, P., <i>et al.</i> , "Incomplete processing of progastrin expressed by human colon cancer cells: role of noncarboxyamidated gastrins," <i>Am. J. Physiol.</i> 266:G459-G468, American Physiological Society (1994)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/535,458 (U.S. Nat'l Phase of Int'l Appl. No. PCT/US03/37206)
				Int'l Filing Date	November 20, 2003
				First Named Inventor	MCLACHLAN, Karen
				Art Unit	1646
				Examiner Name	To Be Assigned
Sheet	3	of	4	Attorney Docket Number	2159.0640005/EKS/PAC/DLL

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL21	Singh, P., <i>et al.</i> , "Role of autocrine and endocrine gastrin-like peptides in colonic carcinogenesis," <i>Curr. Opin. Gastroenterol.</i> 16:68-77, Lippincott Williams & Wilkins (2000)	
	NPL22	Smith, J.P. and Solomon, T.E., "Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer," <i>Gastroenterology</i> 95:1541-1548, W.B. Saunders (1988)	
	NPL23	Sirinek, K.R., <i>et al.</i> , "Pentagastrin Stimulates in Vitro Growth of Normal and Malignant Human Colon Epithelial Cells," <i>Am. J. Surg.</i> 149:35-39, Excerpta Medica (1985)	
	NPL24	Upp, J.R., <i>et al.</i> , "Clinical Significance of Gastrin Receptors in Human Colon Cancers," <i>Cancer Res.</i> 49:488-492, American Association for Cancer Research (1989)	
	NPL25	Van Solinge, W.W., <i>et al.</i> , "Expression but incomplete maturation of progastrin in colorectal carcinomas," <i>Gastroenterology</i> 104:1099-1107, W.B. Saunders (1993)	
	NPL26	Watson, S.A., <i>et al.</i> , "The <i>In Vitro</i> Growth Response of Primary Human Colorectal and Gastric Cancer Cells to Gastrin," <i>Int. J. Cancer</i> 43:692-696, Wiley-Liss (1989)	
	NPL27	Watson, S. and Steele, R., "Distribution, Characterization and Function of Gastrin Receptors Within the Gastrointestinal Tract," in <i>Gastrin Receptors in Gastrointestinal Tumors</i> , R G Landes Co., Austin, Texas, pp 1-99 (1993)	
	NPL28	Weinstock, J. and Baldwin, G.S., "Binding of gastrin-17 to human gastric carcinoma cell lines," <i>Cancer Res.</i> 48:932-937, American Association for Cancer Research (1988)	
	NPL29	Williamson, R.C., <i>et al.</i> , "Promotion of azoxymethane-induced colonic neoplasia by resection of the proximal small bowel," <i>Cancer Res.</i> 38:3212-3217, American Association for Cancer Research (1978)	
	NPL30	Xu Z., <i>et al.</i> , "Gastrin gene expression in human colon cancer cells measured by a simple competitive PCR method," <i>Life Sci.</i> 54:671-678, Pergamon Press (1994)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.